TWI243674B - Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof - Google Patents

Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof Download PDF

Info

Publication number
TWI243674B
TWI243674B TW088113319A TW88113319A TWI243674B TW I243674 B TWI243674 B TW I243674B TW 088113319 A TW088113319 A TW 088113319A TW 88113319 A TW88113319 A TW 88113319A TW I243674 B TWI243674 B TW I243674B
Authority
TW
Taiwan
Prior art keywords
gvg
nicotine
drug
cocaine
drugs
Prior art date
Application number
TW088113319A
Other languages
English (en)
Chinese (zh)
Inventor
Stephen L Dewey
Jonathan D Brodie
Charles R Ashby Jr
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/129,253 external-priority patent/US6057368A/en
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Application granted granted Critical
Publication of TWI243674B publication Critical patent/TWI243674B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW088113319A 1998-08-05 1999-09-29 Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof TWI243674B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/129,253 US6057368A (en) 1998-08-05 1998-08-05 Treatment of addiction and addiction-related behavior
US09/189,166 US6828349B1 (en) 1998-08-05 1998-11-09 Treatment of addiction and addiction-related behavior
US09/209,952 US6541520B1 (en) 1998-08-05 1998-12-11 Treatment of addiction and addiction-related behavior

Publications (1)

Publication Number Publication Date
TWI243674B true TWI243674B (en) 2005-11-21

Family

ID=27383860

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088113319A TWI243674B (en) 1998-08-05 1999-09-29 Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof

Country Status (24)

Country Link
US (4) US6541520B1 (enExample)
EP (1) EP1102583B1 (enExample)
JP (1) JP2002522383A (enExample)
CN (1) CN1172663C (enExample)
AT (1) ATE328588T1 (enExample)
AU (1) AU772715B2 (enExample)
BR (1) BR9912760A (enExample)
CA (1) CA2339192C (enExample)
CY (1) CY1105214T1 (enExample)
CZ (1) CZ2001394A3 (enExample)
DE (1) DE69931789T2 (enExample)
DK (1) DK1102583T3 (enExample)
ES (1) ES2267287T3 (enExample)
HR (1) HRP20010085A2 (enExample)
HU (1) HUP0103377A3 (enExample)
ID (1) ID28916A (enExample)
IL (1) IL141067A0 (enExample)
MX (1) MXPA01001268A (enExample)
NO (1) NO20010539L (enExample)
NZ (1) NZ509682A (enExample)
PL (1) PL198789B1 (enExample)
PT (1) PT1102583E (enExample)
TW (1) TWI243674B (enExample)
WO (1) WO2000007583A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
AU5784499A (en) * 1998-08-25 2000-03-14 Sepracor, Inc. Methods and compositions employing optically pure s(+) vigabatrin
AU759756B2 (en) * 1998-10-20 2003-05-01 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
CN100548290C (zh) * 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
AU4685300A (en) * 1999-04-30 2000-11-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency
IT1313585B1 (it) * 1999-07-30 2002-09-09 Neuroscienze S C A R L Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
US6395783B1 (en) * 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US20020187996A1 (en) * 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US7041650B2 (en) 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7822470B2 (en) * 2001-10-11 2010-10-26 Osypka Medical Gmbh Method for determining the left-ventricular ejection time TLVE of a heart of a subject
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US6797707B2 (en) * 2002-03-29 2004-09-28 University Of Florida Antagonists of RF-amide neuropeptides
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003243699B2 (en) 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
PE20070043A1 (es) * 2005-05-17 2007-02-05 Wm Internat Ltd Aparato y metodo para la estabilizacion no quimica de bio-solidos
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
CA2621560A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
US20100021570A1 (en) * 2006-06-21 2010-01-28 Harlan Clayton Bieley Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
DK2061458T3 (en) * 2006-09-15 2015-03-09 Univ Minnesota Topiramate compositions and methods for their use
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
KR20090119760A (ko) * 2007-01-23 2009-11-19 고리츠다이가쿠호징 나고야시리츠다이가쿠 알츠하이머형 인지증의 예방 및 치료를 위한 의약
BRPI0815089A2 (pt) 2007-08-06 2014-09-30 Synosia Therapeutics Inc Métodos para tratar um paciente que sofre de ou suscetível a pelo menos um sintoma de abuso de, dependência sobre, ou retirada de pelo menos uma substância, para tratar pelo menos uma fase de dependência de substância sobre pelo menos uma substância em um paciente, e para tratar pelo menos uma fase de dependência à cocaína em um paciente.
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CN102573821A (zh) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 保持体重的戒烟法及营养补充剂
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2542234A4 (en) * 2010-02-25 2013-07-31 Univ Northwestern PROCESS FOR USE OF (1S, 3S -) - 3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANIC ACID
US20120046232A1 (en) * 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
KR101647267B1 (ko) 2010-12-22 2016-08-09 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
US9662392B2 (en) * 2014-06-03 2017-05-30 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN114903006B (zh) * 2021-02-09 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物物质成瘾模型的构建方法与应用
WO2022235530A1 (en) * 2021-05-05 2022-11-10 Mind Medicine, Inc. Mdma enantiomers
CN115386421A (zh) * 2022-06-23 2022-11-25 江苏华熙益能生物科技有限公司 烟叶用香精、制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639607A (en) 1970-11-02 1972-02-01 Jack E Phillips Method for treating the tobacco smoking habit
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
NZ194348A (en) * 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
GB2133002B (en) 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
JPH03500411A (ja) 1987-10-07 1991-01-31 マトリックス　テクノロジーズ　インコーポレーテッド コカイン中毒の処置および治療薬
EP0509180A1 (en) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
US5332736A (en) * 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
WO1999021540A2 (en) 1997-10-28 1999-05-06 Schering Corporation Method of reducing craving in mammals
AU759756B2 (en) 1998-10-20 2003-05-01 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
CN100548290C (zh) 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
AU4685300A (en) 1999-04-30 2000-11-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency

Also Published As

Publication number Publication date
MXPA01001268A (es) 2003-07-14
NO20010539D0 (no) 2001-01-31
WO2000007583A2 (en) 2000-02-17
ID28916A (id) 2001-07-12
JP2002522383A (ja) 2002-07-23
ES2267287T3 (es) 2007-03-01
CA2339192A1 (en) 2000-02-17
HUP0103377A3 (en) 2003-11-28
US20020037925A1 (en) 2002-03-28
PL347912A1 (en) 2002-04-22
PT1102583E (pt) 2006-10-31
US6906099B2 (en) 2005-06-14
CN1172663C (zh) 2004-10-27
CA2339192C (en) 2009-12-22
US6541520B1 (en) 2003-04-01
PL198789B1 (pl) 2008-07-31
EP1102583A2 (en) 2001-05-30
HUP0103377A2 (hu) 2002-01-28
EP1102583B1 (en) 2006-06-07
DK1102583T3 (da) 2006-10-09
BR9912760A (pt) 2001-10-09
HRP20010085A2 (en) 2002-02-28
AU772715B2 (en) 2004-05-06
CZ2001394A3 (cs) 2001-08-15
US6593367B1 (en) 2003-07-15
WO2000007583A3 (en) 2000-09-08
US6323239B1 (en) 2001-11-27
CN1326342A (zh) 2001-12-12
ATE328588T1 (de) 2006-06-15
DE69931789D1 (de) 2006-07-20
NO20010539L (no) 2001-04-02
IL141067A0 (en) 2002-02-10
NZ509682A (en) 2004-01-30
CY1105214T1 (el) 2010-03-03
AU5545299A (en) 2000-02-28
DE69931789T2 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
TWI243674B (en) Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof
Popik et al. Pharmacology of ibogaine and ibogaine-related alkaloids
US6890951B2 (en) Treatment of addiction and addiction-related behavior
RU2403030C2 (ru) ПРОИЗВОДНЫЕ α-АМИНОАМИДА, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ СИНДРОМА УСТАЛЫХ НОГ И ВЫЗЫВАЮЩИХ ПРИВЫКАНИЕ РАССТРОЙСТВ
US6828349B1 (en) Treatment of addiction and addiction-related behavior
CN106692144A (zh) 预防和治疗成瘾的组合物和方法
CN102481291A (zh) 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法
Gold From bedside to bench and back again: a 30-year saga
Howard Drugs of abuse: Pharmacology and molecular mechanisms
Berquist et al. In vivo effects of 3, 4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation
Stairs et al. Effects of nornicotine enantiomers on intravenous S (−)-nicotine self-administration and cardiovascular function in rats
Haider et al. Pharmacologic management of parkinsonism and other movement disorders
CN1771929A (zh) 苯环利啶成瘾及苯环利啶成瘾相关行为的治疗
KR20010085332A (ko) 중독 및 중독 관련 행동의 치료
Rathi Chemical Therapeutics for the Treatment of Alcoholism
Foltin et al. The relationship between cocaine venous blood levels and the cardiovascular and subjective effects of smoked and intravenous cocaine
Pudiak The involvement of nitric oxide in cocaine reinforcement processes
Lindsey Effects of monoamine transporter blockers on cocaine self-administration: Relation to dopamine transporter occupancy measured by PET in rhesus monkeys. An investigation of substitute agonist therapeutic strategies for cocaine addiction
Megens Morphine-induced behaviour of cats and neurotransmission processes within raphe, striatal and septal nuclei: introduction of a new method in psychopharmacology
Gessa Preface to the Special Issue
Moolten Pharmacologic and nonpharmacologic influences in the reinforcing effects of ethanol
Craig Analgesics and Sports Medicine
METHADONE PX: 3 X/WEEK LAAM
Short Evidence for an Endogenous Opioid Component in Nicotine Dependence and Abstinence Syndrome
Talavera et al. Rapid Fire Pharmacy Review